{
  "meta": {
    "title": "00217_Mid_Day_Pyqs_Neet_Pg_-_Final_33",
    "url": "https://brainandscalpel.vercel.app/00217-mid-day-pyqs-neet-pg-final-33-8a3a4d04.html",
    "scrapedAt": "2025-11-29T18:14:17.388Z"
  },
  "questions": [
    {
      "id": 8819,
      "choices": [
        {
          "id": 35243,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Gastrocolic</span></span></span></p>"
        },
        {
          "id": 35244,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Enterocolic</span></span></span></p>"
        },
        {
          "id": 35245,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Gastroileal</span></span></span></p>"
        },
        {
          "id": 35246,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Enterogastric</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In which of the following reflexes, gastric emptying is delayed when acidic content enters the duodenum?(NEET PG 2020)</span></span></p>",
      "unique_key": "Q4042093",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959950,
      "difficulty_level": "intermediate",
      "subjects_id": [
        2
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D. Enterogastric </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Enterogastric reflex is the reflex that inhibits gastric emptying. It is elicited by the presence of chyme in the duodenum, which prevents further emptying of stomach.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mechanism of enterogastric reflex</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Presence of chyme in duodenum causes generation of nerve impulses which are transmitted to stomach by the intrinsic nerve fibers of GI tract. After reaching the stomach, these impulses inhibit emptying.</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impulses from duodenum pass via extrinsic </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">sympathetic fibers to stomach and inhibit emptying. </span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Some impulses from duodenum travel through afferent vagal fibers to the brainstem. Normally, brainstem neurons send excitatory impulses to stomach through efferent vagal fibers and stimulate gastric emptying. However, the impulses from duodenum inhibit these brainstem neurons and thereby inhibit gastric emptying.</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Gastrocolic Reflex</span></strong><span style=\"font-size:12.0pt\">: Incorrect. The gastrocolic reflex triggers increased colonic motility in response to food entering the stomach. It does not directly affect gastric emptying.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Enterocolic Reflex</span></strong><span style=\"font-size:12.0pt\">: Incorrect. This is not a widely recognized reflex within standard physiological texts; it does not pertain specifically to the control of gastric emptying.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Gastroileal Reflex</span></strong><span style=\"font-size:12.0pt\">: Incorrect. The gastroileal reflex stimulates the movement of chyme from the ileum into the large intestine following food intake, which is unrelated to the initial inhibition of gastric emptying.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The enterogastric reflex plays a critical role in regulating the rate at which the stomach empties its contents into the duodenum, particularly under conditions where the chyme is highly acidic. This regulation ensures that the duodenum can adequately process the chyme without being overwhelmed, which is crucial for maintaining digestive health and preventing duodenal irritation or damage.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Factors which initiate enterogastric reflex</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Duodenal distension</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Irritation of the duodenal mucosa</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acidity of the chyme</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osmolality of the chyme</span></span></span></li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Breakdown products of proteins and fats</span></span></span></li>\r\n</ol>",
      "correct_choice_id": 35246,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57442,
      "choices": [
        {
          "id": 229141,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clonidine</span></span></p>"
        },
        {
          "id": 229142,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Buprenorphine</span></span></p>"
        },
        {
          "id": 229143,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Butorphanol</span></span></p>"
        },
        {
          "id": 229144,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Naloxone</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is commonly used for maintenance therapy in opioid abuse? (NEET PG 2024)</span></span></span></p>",
      "unique_key": "Q2577077",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959956,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Buprenorphine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maintenance therapy in opioid dependence involves the use of <strong>long-acting opioids</strong> to stabilize the patient and prevent withdrawal symptoms, thus helping them gradually reduce dependency on more harmful opioids. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Buprenorphine is a partial opioid agonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> that binds to the same receptors as other opioids but with a lower intrinsic activity, meaning it produces less euphoria and has a ceiling effect that reduces the risk of misuse. Additionally, buprenorphine has a long half-life, which makes it suitable for maintenance therapy as it allows for once-daily dosing and reduces withdrawal symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Another common medication used for maintenance therapy is <strong>methadone</strong>, a full opioid agonist. However, buprenorphine is often preferred due to its safety profile, particularly the lower risk of overdose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Clonidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clonidine is an alpha-2 adrenergic agonist used to manage symptoms of opioid withdrawal, particularly by reducing sympathetic overactivity (e.g., sweating, agitation, and anxiety). However, it is not used for maintenance therapy but rather for symptom control during detoxification.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Butorphanol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Butorphanol is an opioid analgesic that can be used for pain management. It is not typically used for maintenance therapy in opioid addiction and has potential for misuse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Naloxone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Naloxone is an opioid antagonist used to reverse opioid overdose. It does not have a role in maintenance therapy but is crucial for emergency management of opioid toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methadone&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and <strong>buprenorphine</strong> are long-acting opioids used for maintenance therapy in opioid addiction. They replace the addictive opioid to prevent withdrawal symptoms.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To treat withdrawal symptoms:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diazepam</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (a benzodiazepine) is used for seizures.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clonidine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> or beta blockers are used for sympathetic symptoms.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Naltrexone</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is used to prevent relapse in opioid addiction.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 229142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11259,
      "choices": [
        {
          "id": 45002,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop oral methotrexate and start parenteral methotrexate</span></span></span></span></p>"
        },
        {
          "id": 45003,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add sulfasalazine and hydroxychloroquine</span></span></span></span></p>"
        },
        {
          "id": 45004,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continue corticosteroids and methotrexate</span></span></span></span></p>"
        },
        {
          "id": 45005,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start only anti-TNF alpha agents</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with rheumatoid arthritis is being treated with methotrexate and low-dose corticosteroids for the past 4 months. However, the disease is still progressing. What would be your recommendation for the further management of this patient? (NEET PG 2019)</span></span></p>",
      "unique_key": "Q9017136",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959825,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Add sulfasalazine and hydroxychloroquine</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adding sulfasalazine and hydroxychloroquine to the treatment regimen for a patient with rheumatoid arthritis who is not responding adequately to methotrexate and low-dose corticosteroids is a sound strategy. This approach follows the principle of combining different disease-modifying antirheumatic drugs (DMARDs) to achieve better disease control. Both sulfasalazine and hydroxychloroquine are DMARDs that work by different mechanisms to reduce inflammation and slow disease progression in rheumatoid arthritis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Stop oral methotrexate and start parenteral methotrexate:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While switching to parenteral administration can increase the effectiveness of methotrexate for some patients, it might not be sufficient alone if the disease is still progressing.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Continue corticosteroids and methotrexate:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continuing the same treatment without modification is not advisable if the disease is actively progressing, as this indicates that the current regimen is insufficient.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Start only anti-TNF alpha agents:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While anti-TNF agents are effective for many patients, they are typically used after trying combination DMARD therapy, especially in cases not severe enough to warrant immediate biologic therapy.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When a patient with rheumatoid arthritis does not respond adequately to initial therapy with methotrexate and corticosteroids, the addition of other DMARDs such as sulfasalazine and hydroxychloroquine can be beneficial.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start 10mg/week &rarr; max 25mg/week along with Folic acid twice/week</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Check ocular fundus before HCQ initiation</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leflunomide, sulfasalazine other group of drugs.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><strong><em><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sulfasalazine is safe in pregnancy !!</span></span></em></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Arial,sans-serif\"><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Symptomatic relief with NSAID and short course corticosteroids.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reference - Harrison/Rheumatoid arthritis/ Chap 358</span></span></strong></p>",
      "correct_choice_id": 45003,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "OlderNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20390,
      "choices": [
        {
          "id": 81521,
          "text": "<p><span style=\"font-size:12.0pt;\">Ghon technique</span></p>"
        },
        {
          "id": 81522,
          "text": "<p><span style=\"font-size:12.0pt;\">Letulle technique</span></p>"
        },
        {
          "id": 81523,
          "text": "<p><span style=\"font-size:12.0pt;\">Virchow technique</span></p>"
        },
        {
          "id": 81524,
          "text": "<p><span style=\"font-size:12.0pt;\">Rokitansky technique</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 42-year-old HIV-positive patient died, and his body was brought for post-mortem. The method of autopsy to be done is:</span><span style=\"font-size:11.0pt;\">&nbsp;(</span><span style=\"font-size:12.0pt;\">NEET PG 2023)</span></p>",
      "unique_key": "Q7537928",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959953,
      "difficulty_level": "beginner",
      "subjects_id": [
        10
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D. Rokitansky technique</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Rokitansky Method-</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">In situ</span></li><li><span style=\"font-size:12.0pt;\">Organs dissected inside the body</span></li><li><span style=\"font-size:12.0pt;\">for highly infectious disease, e.g., HIV to prevent the spread of infection</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">&nbsp;<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/04/image_lcppCca.png\" width=\"321\" height=\"283\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Rokitansky Method</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Ghon’s method (en block):</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Cervical, thoracic abdominal and pelvic organs are removed in separate blocks</span></p><p>&nbsp;</p><p><span style=\"font-size:18px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/04/image-20240604162229-2.png\" width=\"231\" height=\"212\"><strong>&nbsp;</strong></span></p><p><span style=\"font-size:12.0pt;\">Ghon’s Method</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Letulle’s method (En masse)</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Thoracic, cervical, abdominal, and pelvic organs are removed \"en masse,\" as one big organ block.</span></li><li><span style=\"font-size:12.0pt;\">Best technique to see relations amongst organs.</span></li><li><span style=\"font-size:12.0pt;\">Preferred in infants so that congenital abnormalities in different organs can be seen in relation to each other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">Disadvantage: difficult to handle large mass.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\">&nbsp; &nbsp; &nbsp;&nbsp;<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/04/image_a4ISBHJ.png\" width=\"380\" height=\"204\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">Letulle’s Method</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Virchow’s method</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Each and every organ is removed one by one (e.g., each lung, each kidney, heart separately)</span></li><li><span style=\"font-size:12.0pt;\">Relations of organs are not preserved</span></li><li><span style=\"font-size:12.0pt;\">Most commonly used technique (easier to perform)</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:18px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/04/image-20240604162229-4.png\" width=\"298\" height=\"171\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Virchow’s Method</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The Rokitansky technique involves dissecting organs in situ and is the preferred method for highly infectious diseases like HIV to prevent the spread of infection.</span></p>",
      "correct_choice_id": 81524,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73698,
      "choices": [
        {
          "id": 293733,
          "text": "<p><span style=\"font-size:12.0pt;\">At high doses in elderly patients, it causes cardiotoxicity and in younger patients nephrotoxicity</span></p>"
        },
        {
          "id": 293734,
          "text": "<p><span style=\"font-size:12.0pt;\">Adverse effects can be avoided if the dose is kept less than 250 mg phenytoin sodium equivalents</span></p>"
        },
        {
          "id": 293735,
          "text": "<p><span style=\"font-size:12.0pt;\">It is given to all seizure patients in emergency irrespective of CNS adverse effects and hypotension</span></p>"
        },
        {
          "id": 293736,
          "text": "<p><span style=\"font-size:12.0pt;\">High oral dose can result in cerebellar degeneration</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of the following statements is true regarding fosphenytoin?&nbsp;(INICET NOV 2024)</span></p>",
      "unique_key": "Q4923947",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959823,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Adverse effects can be avoided if the dose is kept less than 250 mg phenytoin sodium equivalents</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:16px;\">Fosphenytoin is a water-soluble prodrug of phenytoin used for IV administration. When the dose is kept below 250 mg phenytoin sodium equivalents, adverse effects can be minimized. This dosing guideline helps prevent complications while maintaining therapeutic efficacy. After administration, fosphenytoin is converted to phenytoin by phosphatases in blood and liver.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong>&nbsp;</span></p><p><br><span style=\"font-size:16px;\"><strong>Option A. At high doses in elderly patients, it causes cardiotoxicity and in younger patients nephrotoxicity</strong> - Incorrect. Cardiotoxicity can occur at high doses in all age groups, not just elderly. There is no specific age-related difference in nephrotoxicity.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. It is given to all seizure patients in emergency irrespective of CNS adverse effects and hypotension</strong> - Incorrect. While it's useful in emergency situations, it's not given indiscriminately. CNS effects and hypotension need to be monitored and managed.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. High oral dose can result in cerebellar degeneration -</strong> Incorrect. Fosphenytoin is given intravenously, not orally. While phenytoin can cause cerebellar degeneration, this statement is incorrect for fosphenytoin's route of administration.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:16px;\">Fosphenytoin's adverse effects can be minimized by keeping the dose below 250 mg phenytoin sodium equivalents, and it is specifically designed for IV administration.</span></p>",
      "correct_choice_id": 293734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8834,
      "choices": [
        {
          "id": 35303,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Interstitial</span></span></span></p>"
        },
        {
          "id": 35304,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Intracellular fluid</span></span></span></p>"
        },
        {
          "id": 35305,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Extracellular fluid</span></span></span></p>"
        },
        {
          "id": 35306,
          "text": "<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Plasma</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A body fluid sample is being studied and has Na: 10 mEq/L, K: 140 mEq/L, CI: 4 mE/L. Identify the compartment from which the sample has been obtained?&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2021)</span></span></p>",
      "unique_key": "Q5113291",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959827,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B. Intracellular fluid </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The electrolyte composition in the sample obtained has high concentration of potassium, suggests that it is intracellular fluid (IC) compartment.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/10/694.jpg\" style=\"height:520px; width:779px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Interstitial and Option C. Extracellular Fluid</span></strong><span style=\"font-size:12.0pt\"> generally have higher sodium and chloride concentrations and much lower potassium concentrations.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Plasma</span></strong><span style=\"font-size:12.0pt\">, part of the extracellular fluid, would similarly show higher sodium and chloride but lower potassium.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The composition of potassium, sodium, and chloride in the sample aligns with that typically found in intracellular fluid, reflecting its origin from within cells, where potassium is the major cation, unlike extracellular compartments dominated by sodium and chloride.</span></span></span></p>",
      "correct_choice_id": 35304,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5301,
      "choices": [
        {
          "id": 21176,
          "text": "<p><span style=\"font-size:12.0pt;\">P. falciparum</span></p>"
        },
        {
          "id": 21177,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿P. malariae</span></p>"
        },
        {
          "id": 21178,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿P. ovale</span></p>"
        },
        {
          "id": 21179,
          "text": "<p><span style=\"font-size:12.0pt;\">﻿﻿﻿P. vivax</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a 30-year-old female from a tribal area who presents with fever for the last 3 days, which of the following is the most likely causative agent of her illness based on the diagnosis of malaria made through examination of the peripheral smear?</span><span style=\"font-size:10.5pt;\"> (</span><span style=\"font-size:12.0pt;\">NEET PG 2020)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/01/1_vgK36SJ.jpg\" alt=\"\" width=\"300\" height=\"267\"></span></p>",
      "unique_key": "Q4731687",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959957,
      "difficulty_level": "beginner",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) P. falciparum</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image shows ring forms/ early trophozoites in erythrocyte, which are binucleate (double chromatin) resembling <strong>stereo headphones</strong> in appearance, characteristic of P. falciparum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">There may be several rings present within a single erythrocyte. The rings are often attached to the margins of the red cells and are described as form <u>applique or accole</u>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. P. malariae:</strong> Causes quartan malaria with a longer incubation period and typically presents with band-form trophozoites across the red cells, distinct from the forms seen in P. falciparum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. P. ovale:</strong> Known for causing tertian malaria with similar clinical presentations to P. vivax, including the presence of Schüffner's dots and slightly enlarged and ovale-shaped erythrocytes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. P. vivax:</strong> Also causes tertian malaria, characterized by Schüffner's stippling in erythrocytes, larger ring forms than P. falciparum, and less severe disease outcomes compared to P. falciparum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Identification of P. falciparum through the presence of distinctive ring forms in red blood cells on a peripheral smear is crucial for rapid initiation of appropriate antimalarial therapy, particularly in endemic regions. Early treatment is vital to prevent severe complications and reduce the morbidity and mortality associated with this malaria species.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/0004_zwS4Chh.png\" width=\"737\" height=\"826\"></p>",
      "correct_choice_id": 21176,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54952,
      "choices": [
        {
          "id": 219269,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Edward syndrome</span></span></p>"
        },
        {
          "id": 219270,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Turner syndrome</span></span></p>"
        },
        {
          "id": 219271,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patau syndrome</span></span></p>"
        },
        {
          "id": 219272,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Down syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which trisomy is suggested by karyotyping results showing chromosomal defects? (FMGE JULY 2024)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/27/5_62287365066771709315.jpg\" style=\"height:242px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q1364128",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959962,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Edward syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The karyotyping result showing an extra chromosome at the level of chromosome 18 indicates Trisomy 18, which is characteristic of Edward syndrome. Edward syndrome is a genetic disorder caused by the presence of all or part of an extra 18th chromosome. This condition leads to severe developmental delays, congenital heart defects, and other abnormalities. The karyotype typically shows three copies of chromosome 18 instead of the usual two.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Turner syndrome:</span></strong><span style=\"font-size:12.0pt\"> Turner syndrome is not associated with trisomy. Instead, it is characterized by the presence of a single X chromosome (45,X) in females. It is a monosomy condition, not a trisomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Patau syndrome:</span></strong><span style=\"font-size:12.0pt\"> Patau syndrome is associated with Trisomy 13, where there is an extra chromosome 13. The karyotype shows three copies of chromosome 13, not 18.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Down syndrome:</span></strong><span style=\"font-size:12.0pt\"> Down syndrome is caused by Trisomy 21, characterized by an extra chromosome 21. The karyotype shows three copies of chromosome 21, not 18.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Edward syndrome is caused by Trisomy 18, where the karyotype reveals an extra chromosome 18. This distinguishes it from other chromosomal disorders such as Down syndrome (Trisomy 21) and Patau syndrome (Trisomy 13)</span></span></span></p>",
      "correct_choice_id": 219269,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "FMGE",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54822,
      "choices": [
        {
          "id": 218753,
          "text": "<p><span style=\"font-size:12.0pt;\">Axial flap</span></p>"
        },
        {
          "id": 218754,
          "text": "<p><span style=\"font-size:12.0pt;\">Rotation flap</span></p>"
        },
        {
          "id": 218755,
          "text": "<p><span style=\"font-size:12.0pt;\">Advancement flap</span></p>"
        },
        {
          "id": 218756,
          "text": "<p><span style=\"font-size:12.0pt;\">Transposition flap</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following procedure is done for the treatment of Pilonidal sinus as shown?&nbsp;(FMGE JULY 2024)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-164507.png\" alt=\"\" width=\"300\" height=\"215\"></span></p>",
      "unique_key": "Q1574259",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959951,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D) Transposition flap</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image provided shows a surgical procedure used to treat a pilonidal sinus. The procedure depicted is a <strong>Limberg flap</strong>, also known as a <strong>rhomboid flap</strong>. In this technique, a rhomboid-shaped piece of tissue adjacent to the excision site is cut and transposed to cover the wound created after the excision of the pilonidal sinus. This movement of tissue from the side to the gap is characteristic of a transposition flap. The Limberg flap is effective for ensuring tension-free closure and reducing the recurrence of the pilonidal sinus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Axial flap:</strong> This type of flap involves tissue that has a specific blood supply along its axis, which is not depicted in the image provided.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Rotation flap:</strong> A rotation flap involves rotating tissue around a pivot point to cover a defect. The image shows transposition rather than rotation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Advancement flap:</strong> This involves moving tissue forward to cover a defect, typically in a straight line, which is not shown in the image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The Limberg flap, used in the treatment of pilonidal sinus, is a type of transposition flap where tissue from the adjacent side is cut, rotated, and used to close the defect created by the excision of the pilonidal sinus.</span></p>",
      "correct_choice_id": 218756,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "FMGE",
        "ImageBased",
        "InstrumentsBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54936,
      "choices": [
        {
          "id": 219205,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coagulative necrosis</span></span></span></p>"
        },
        {
          "id": 219206,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Caseous necrosis</span></span></span></p>"
        },
        {
          "id": 219207,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fat necrosis</span></span></span></p>"
        },
        {
          "id": 219208,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fibrinoid necrosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A chronic alcoholic patient presents with lower back pain and fever. She has elevated amylase levels and has experienced similar episodes in the past as well. Which type of necrosis is likely to be present? (FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q9398942",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959960,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Fat necrosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with symptoms suggestive of pancreatitis, including lower back pain, fever, elevated amylase levels, and a history of chronic alcohol use. <strong>Pancreatitis</strong> is a condition where inflammation of the pancreas occurs, often due to long-term alcohol consumption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In pancreatitis, the digestive enzymes, particularly lipases, are released into the pancreas and surrounding tissues, leading to the breakdown of fat cells. This enzymatic activity causes fat necrosis, a process where fatty acids combine with calcium to form chalky white areas known as saponification. This type of necrosis is characteristic of chronic pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common precipitating factor for an acute pancreatitis attack is cholelithiasis (gallstones). Chronic pancreatitis, on the other hand, is typically associated with a long-standing history of alcohol intake.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coagulative necrosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Typically occurs <strong>in ischemic conditions</strong> (except in the brain) and is not associated with the enzymatic activity seen in pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Caseous necrosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Commonly associated with <strong>tuberculosis</strong>, it has a cheese-like appearance and is not related to pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Fibrinoid necrosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Involves <strong>immune complex deposition</strong> in blood vessels and is seen in conditions like vasculitis and certain autoimmune diseases, not in pancreatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fat necrosis is a hallmark of pancreatitis, particularly in the context of chronic alcohol use. It is caused by the action of pancreatic enzymes on surrounding fat tissue, leading to saponification and calcium deposition.</span></span></span></p>",
      "correct_choice_id": 219207,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7577,
      "choices": [
        {
          "id": 30276,
          "text": "<p><span style=\"font-size:12pt;\">Lichen planus</span></p>"
        },
        {
          "id": 30277,
          "text": "<p><span style=\"font-size:12pt;\">Psoriasis</span></p>"
        },
        {
          "id": 30278,
          "text": "<p><span style=\"font-size:12pt;\">Vitiligo</span></p>"
        },
        {
          "id": 30279,
          "text": "<p><span style=\"font-size:12pt;\">Alopecia areata</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Irregular pitting of the nails with subungual hyperkeratosis is seen in? (NEET PG 2022)</span></p>",
      "unique_key": "Q2951229",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959964,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><i><strong>Ans.</strong></i></span><span style=\"color:#0782c1;font-size:12pt;\"><i><strong>&nbsp;</strong></i></span><span style=\"font-size:12pt;\"><strong>B. Psoriasis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Irregular pitting</strong> of the nails with <strong>subungual hyperkeratosis</strong> is most commonly seen in <strong>psoriasis</strong>, which is a <strong>chronic inflammatory</strong> skin condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Psoriasis</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">It is an <strong>inflammatory non-infectious</strong> disease characterized by an <strong>imbalance in T-cell subsets.</strong> There is an <strong>elevated number of activated Th1, Th17, and Th22 cells, while Th2 cells are deficient.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Cytokines in psoriasis:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/15/screenshot-2024-06-15-133321.png\" alt=\"\" width=\"900\" height=\"186\"></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Genetic predisposition:</strong></span> <span style=\"font-size:12pt;\">n <strong>Type 1</strong> plaque psoriasis and <strong>guttate</strong> psoriasis with HLA <strong>C:06:02 association</strong>.</span></li><li><span style=\"font-size:12pt;\">Around <strong>5-30%</strong> of individuals with cutaneous psoriasis also develop <strong>psoriatic arthritis</strong> (PsA), a condition affecting the joints.</span></li><li><span style=\"font-size:12pt;\">Psoriasis can affect the <strong>skin and joints</strong>, leading to <strong>psoriatic arthritis.</strong></span></li><li><span style=\"font-size:12pt;\">About <strong>5-30%</strong> of patients with <strong>cutaneous</strong> psoriasis have <strong>psoriatic arthritis (PsA)</strong>.</span></li><li><span style=\"font-size:12pt;\">At any given time, <strong>40%</strong> of psoriasis cases have changes to their <strong>nails</strong>.</span></li><li><span style=\"font-size:12pt;\">Nail psoriasis is linked to more <strong>severe psoriasis</strong>, <strong>longer disease duration</strong>, <strong>psoriatic arthritis</strong>, and <strong>family</strong> history of the condition.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Nail changes in psoriasis:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/15/screenshot-2024-06-15-133332.png\" alt=\"\" width=\"900\" height=\"230\"></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Salmon patches</strong></span> <span style=\"font-size:12pt;\">or <strong>subungual oil drop sign</strong> is extremely specific <strong>pathognomonic</strong> sign of nail psoriasis. It looks like an <strong>oil</strong> droplet and is a <strong>yellowish</strong>, <strong>reddish</strong> discoloration in the nail bed.</span></li><li><span style=\"font-size:12pt;\">However, the most frequent symptom is nail <strong>pitting</strong>.</span></li><li><span style=\"font-size:12pt;\">Individual pits are <strong>irregular</strong> in shape and uniform in <strong>depth</strong>. These nail pits, also referred to as <strong>Thimble</strong> <strong>pits</strong>, are brought on by the <strong>proximal</strong> <strong>nail</strong> <strong>matrix's</strong> involvement.</span></li><li><span style=\"font-size:12pt;\"><strong>Subungual</strong> <strong>hyperkeratosis</strong>, <strong>splinter</strong> <strong>hemorrhages</strong>, and <strong>distal</strong> <strong>onycholysis</strong> are additional symptoms of nail bed disease.</span></li><li><span style=\"font-size:12pt;\">There might also be <strong>leukonychia</strong>.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/20/picture3.jpg\" alt=\"\" width=\"400\" height=\"300\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/20/picture4.jpg\" alt=\"\" width=\"400\" height=\"248\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/20/picture5.jpg\" alt=\"\" width=\"400\" height=\"317\"></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/20/picture6_xhbPtxQ.jpg\" alt=\"\" width=\"500\" height=\"359\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Lichen planus:</strong></span></p><ul><li><span style=\"font-size:12pt;\">Lichen planus can affect the nails and produce nail changes, but the common manifestations are <strong>nail thinning, ridging</strong>, or even complete loss of the nail.</span></li><li><span style=\"font-size:12pt;\"><strong>Pterygium formation</strong>, where there's scarring of the cuticle area leading to the nail's progressive loss, can also be seen.</span></li><li><span style=\"font-size:12pt;\">While lichen planus can cause nail pitting, it's typically not associated with <strong>subungual hyperkeratosis</strong>, a feature <strong>more consistent with psoriasis</strong>.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Vitiligo:</strong></span></p><ul><li><span style=\"font-size:12pt;\">Vitiligo is a disorder where there's a <strong>loss of pigment-producing cells</strong> (melanocytes) leading to <strong>white patches</strong> on the skin.</span></li><li><span style=\"font-size:12pt;\">It doesn't typically produce pitting of nails.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D: Alopecia areata</strong>:</span></p><p><span style=\"font-size:12pt;\"><strong>Geometric fine stippled pitting (Superficial, Regular, Fine)</strong> of the nails is the most likely expected finding as shown below.</span></p><p>&nbsp;</p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/20/picture7.jpg\" alt=\"\" width=\"400\" height=\"356\"></span></p><p>&nbsp;</p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/15/screenshot-2024-06-15-133344.png\" alt=\"\" width=\"900\" height=\"104\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Psoriasis</strong> is the condition most commonly associated with <strong>irregular nail pitting</strong> and <strong>subungual hyperkeratosis</strong> among the options provided.</span></p><p>&nbsp;</p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Reference:</strong></span></p><p><span style=\"font-size:12pt;\"><strong>Rooks textbook of dermatology- 9<sup>th</sup> Edition page no 4.9, 35.4-35.34, 37.12, 41.1, 41.21 89.28-33</strong></span></p><p><span style=\"font-size:12pt;\"><strong>Harrison’s principles of internal medicine 20<sup>th</sup> edition Page no 333</strong></span></p>",
      "correct_choice_id": 30277,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 33866,
      "choices": [
        {
          "id": 135302,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel</span></p>"
        },
        {
          "id": 135303,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        },
        {
          "id": 135304,
          "text": "<p><span style=\"font-size:12.0pt;\">Betrixaban</span></p>"
        },
        {
          "id": 135305,
          "text": "<p><span style=\"font-size:12.0pt;\">Enoxaparin</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A pregnant female in first trimester developed deep vein thrombosis. She requires anticoagulation. Which of the following will be the preferred drug in this patient?</span> <span style=\"font-size:12.0pt;\">(Fmge Jan 2024)</span></p>",
      "unique_key": "Q7688670",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959954,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. D. Enoxaparin</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Enoxaparin is the preferred drug for a pregnant female with DVT, particularly in the first trimester. Its safety profile and effectiveness in treating and preventing DVT make it suitable for use in pregnancy. The other options either have safety concerns during pregnancy or are not typically used for the treatment of DVT.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A.</strong> <strong>Clopidogrel:</strong> This is an antiplatelet drug, not typically used in the treatment of DVT, and its safety in pregnancy is not well-established.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B.</strong> <strong>Warfarin:</strong> Warfarin is a vitamin K antagonist and is generally contraindicated in pregnancy, especially during the first trimester, due to the risk of teratogenic effects (warfarin embryopathy).</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.</strong> <strong>Betrixaban:</strong> This is an oral Factor Xa inhibitor. The safety of betrixaban in pregnancy has not been established, and it is generally not recommended.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Enoxaparin, a low molecular weight heparin (LMWH) is the preferred choice for anticoagulation in pregnancy because they do not cross the placenta and thus have a lower risk of fetal harm. Enoxaparin is effective in the treatment and prevention of DVT and is considered safe for use in pregnancy.</span></p>",
      "correct_choice_id": 135305,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54268,
      "choices": [
        {
          "id": 216541,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypercortisolism</span></span></p>"
        },
        {
          "id": 216542,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperthyroidism</span></span></p>"
        },
        {
          "id": 216543,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperparathyroidism</span></span></p>"
        },
        {
          "id": 216544,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperaldosteronism</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 45-year-old man presented with weight gain, proximal muscle weakness, purple striae, and easy bruising. What is the likely underlying condition?</span></span></span>&nbsp;(INICET MAY 2024)</p>",
      "unique_key": "Q3026143",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959963,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Hypercortisolism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypercortisolism, also known as Cushing&#39;s syndrome, is characterized by an excess of cortisol in the body. The clinical features of Cushing&#39;s syndrome include weight gain, particularly in the face, neck, and trunk, proximal muscle weakness, purple striae (stretch marks), and easy bruising. These symptoms are a result of the catabolic effects of cortisol on various tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Weight Gain:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Cortisol promotes the deposition of fat in specific areas, leading to central obesity.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Proximal Muscle Weakness:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Cortisol has catabolic effects on muscle tissue, leading to muscle wasting and weakness, particularly in the proximal muscles.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Purple Striae:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Cortisol weakens the skin by breaking down collagen, leading to the formation of purple striae.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Easy Bruising:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Cortisol reduces the ability of blood vessels to repair themselves, causing increased bruising.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Hyperthyroidism:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This condition involves an excess of thyroid hormones, leading to symptoms such as weight loss, increased appetite, heat intolerance, and hyperactivity. It does not typically cause the symptoms described in the question.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Hyperparathyroidism:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This condition involves an excess of parathyroid hormone, leading to hypercalcemia, bone pain, kidney stones, and abdominal pain. It does not cause the symptoms described in the question.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Hyperaldosteronism:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This condition involves an excess of aldosterone, leading to hypertension and hypokalemia. It does not cause the symptoms described in the question.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing&#39;s syndrome, or hypercortisolism, is characterized by weight gain, proximal muscle weakness, purple striae, and easy bruising due to the catabolic effects of excess cortisol.</span></span></p>",
      "correct_choice_id": 216541,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 48252,
      "choices": [
        {
          "id": 192603,
          "text": "<p><span style=\"font-size:12.0pt;\">The most common mechanism involves the production of neutralizing enzymes by bacteria.</span></p>"
        },
        {
          "id": 192604,
          "text": "<p><span style=\"font-size:12.0pt;\">Plasmid-mediated resistance is transmitted exclusively through vertical transmission.</span></p>"
        },
        {
          "id": 192605,
          "text": "<p><span style=\"font-size:12.0pt;\">The complete elimination of the target binding site may contribute to vancomycin resistance in some enterococci.</span></p>"
        },
        {
          "id": 192606,
          "text": "<p><span style=\"font-size:12.0pt;\">Alteration of the target binding site contributes to antibiotic resistance in Streptococcus pneumoniae.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Regarding antibiotic resistance, which of the following statements is <strong>NOT</strong> true? (NEET PG 2016)</span></p>",
      "unique_key": "Q8839696",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959967,
      "difficulty_level": "intermediate",
      "subjects_id": [
        6
      ],
      "solution": "<p><strong>Correct Answer: B. Plasmid-mediated resistance is transmitted exclusively through vertical transmission.</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p><br><strong>Plasmid-mediated resistance</strong> is NOT transmitted exclusively through vertical transmission. This statement is false because plasmids are primarily transferred horizontally between bacteria through conjugation (direct cell-to-cell contact), transduction (via bacteriophages), or transformation (uptake of DNA from the environment). This horizontal transfer is what makes plasmid-mediated resistance particularly problematic in clinical settings.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option A. The most common mechanism involves the production of neutralizing enzymes by bacteria</strong> - This is true. Many bacteria produce enzymes like beta-lactamases that can degrade or modify antibiotics, rendering them ineffective. This is a major mechanism of resistance against beta-lactam antibiotics.</p><p>&nbsp;</p><p><strong>Option C. The complete elimination of the target binding site may contribute to vancomycin resistance in some enterococci</strong> - This is true. Vancomycin-resistant enterococci (VRE) can alter peptidoglycan precursors so they no longer contain the D-Ala-D-Ala terminal sequences to which vancomycin binds.</p><p>&nbsp;</p><p><strong>Option D. Alteration of the target binding site contributes to antibiotic resistance in Streptococcus pneumoniae</strong> - This is true. S. pneumoniae can develop resistance to penicillins through alterations in penicillin-binding proteins (PBPs), which are the target binding sites for beta-lactam antibiotics.</p><p>&nbsp;</p><p><strong>Educational Objective:</strong></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Plasmid-mediated resistance is primarily spread through horizontal gene transfer mechanisms (conjugation, transduction, and transformation), making it particularly efficient at spreading resistance genes within bacterial populations and between different bacterial species.</span></p>",
      "correct_choice_id": 192604,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4584,
      "choices": [
        {
          "id": 18312,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucose</span></p>"
        },
        {
          "id": 18313,
          "text": "<p><span style=\"font-size:12.0pt;\">Long chain fatty acid</span></p>"
        },
        {
          "id": 18314,
          "text": "<p><span style=\"font-size:12.0pt;\">Lactic acid</span></p>"
        },
        {
          "id": 18315,
          "text": "<p><span style=\"font-size:12.0pt;\">Triglycerides</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An infant present with hypotonia and seizures. It was confirmed to be cerebrohepatorenal syndrome. Which of the following is accumulated in the brain in cerebrohepatorenal syndrome?&nbsp;&nbsp;(NEET PG 2019)</span></p>",
      "unique_key": "Q7270540",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959955,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Long chain fatty acid</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Long-chain fatty acids<strong>&nbsp;</strong>are the substances that accumulate in the brain of individuals with cerebrohepatorenal syndrome, contributing to the neurological symptoms such as hypotonia and seizures. This accumulation disrupts normal brain function and leads to the characteristic clinical features of the syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>A. Glucose:</strong> Glucose is a normal energy source for the brain and is not typically accumulated in the brain in this syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>C. Lactic acid:</strong> While lactic acid can accumulate in some metabolic disorders, it is not the primary substance that accumulates in cerebrohepatorenal syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D. Triglycerides:</strong> Triglycerides are a form of fat storage and are not typically accumulated in the brain in this syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Zellweger syndrome or Cerebrohepatorenal syndrome is due to defective oxidation of very long chain fatty acids (VLCFA</strong>). Peroxisomal enzymes are produced; but their entry into peroxisome is denied. This leads to insufficient oxidation of VLCFA. <strong>Accumulation of VLCFA in CNS causes profound neurologic impairment</strong> and death in childhood.</span></p>",
      "correct_choice_id": 18313,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 35317,
      "choices": [
        {
          "id": 141075,
          "text": "<p><span style=\"font-size:12.0pt;\">Extradural hemorrhage</span></p>"
        },
        {
          "id": 141076,
          "text": "<p><span style=\"font-size:12.0pt;\">Subarachnoid hemorrhage</span></p>"
        },
        {
          "id": 141077,
          "text": "<p><span style=\"font-size:12.0pt;\">Subdural hematoma</span></p>"
        },
        {
          "id": 141078,
          "text": "<p><span style=\"font-size:12.0pt;\">Intraparenchymal hemorrhage</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which type of intracranial hemorrhage is most likely depicted in the given image?&nbsp;(FMGE JAN 2024)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/14/picture48.jpg\" alt=\"\" width=\"250\" height=\"217\"></span></p>",
      "unique_key": "Q1967599",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959966,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Subdural hematoma&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The image provided shows a computed tomography (CT) scan of the brain with a collection of blood within the skull but outside the brain tissue.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">This type of hemorrhage occurs beneath the dura mater and above the arachnoid layer. It commonly appears as a crescent-shaped collection that can cross suture lines but is limited by dural attachments such as the falx and tentorium.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Extradural hemorrhage (also known as epidural hematoma):</strong> Typically biconvex in shape and does not cross suture lines due to the firm attachment of the dura to the skull at the sutures. It is often associated with a skull fracture and middle meningeal artery rupture.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Subarachnoid hemorrhage:</strong> Blood is located under the arachnoid membrane, in the subarachnoid space, where cerebrospinal fluid circulates. On a CT scan, it appears as areas of increased density in the sulci and cisterns, rather than a localized collection.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Intraparenchymal hemorrhage:</strong> This is bleeding directly into the brain tissue and appears as a localized area of increased density within the brain parenchyma itself.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The crescent-shaped collection of blood on a CT scan that can cross suture lines but is limited by dural reflections is indicative of a subdural hematoma, a type of intracranial hemorrhage that occurs between the dura mater and the arachnoid layer.</span></p>",
      "correct_choice_id": 141077,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "FMGE",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11360,
      "choices": [
        {
          "id": 45406,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">600000 IU Once in 3 weeks for 5 years</span></span></span></p>"
        },
        {
          "id": 45407,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">600000 IU Once in 3 weeks for 10 years</span></span></span></p>"
        },
        {
          "id": 45408,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1200000 IU Once in 3 weeks for 10 years</span></span></span></p>"
        },
        {
          "id": 45409,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1200000 IU Once in 3 weeks for life</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">An 11-year-old child who weighs 26 kg with a history of streptococcal pharyngitis presents to you with fever and arthralgia. There is no past history of rheumatic heart disease or features of carditis or valvular disease. How often is benzathine penicillin recommended for prophylaxis of rheumatic heart disease? (Neet pg 2022)</span></span></span></p>",
      "unique_key": "Q6962131",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959829,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. 600000 IU Once in 3 weeks for 10 years</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For secondary prophylaxis of rheumatic fever, especially in patients without carditis or valvulitis, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend administering benzathine penicillin G for either 5 years or until the patient is 21 years old, whichever is longer. Given that the child in this case is 11 years old, prophylaxis should continue until the child turns 21, resulting in a total duration of 10 years.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dosage of benzathine penicillin G depends on the patient&#39;s weight:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For children weighing less than 27 kg, the dose is 600,000 IU.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For children weighing 27 kg or more, the dose is 1,200,000 IU.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the child weighs 26 kg, the appropriate dose is 600,000 IU. In high-risk areas such as India, the injection is administered every 3 weeks to ensure effective prophylaxis against recurrent streptococcal infections that could lead to rheumatic fever.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Note - Treatment duration options for a patient with valvulitis:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Standard Treatment Duration</span></strong><span style=\"font-size:12.0pt\">: Patients can be treated for a total duration of 10 years or until they reach the age of 40, whichever comes later. This approach is likely considered for cases where the valve damage is not extensively severe or life-threatening.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Severe Valve Damage</span></strong><span style=\"font-size:12.0pt\">: If there is severe damage to the valves, such as cases leading to or involving heart failure, lifelong therapy is recommended. This could include ongoing medication to manage the condition and potentially surgical interventions like valve replacement to address the mechanical deficits caused by the damage.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Note &ndash; </span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">First-Line Therapy</span></strong><span style=\"font-size:12.0pt\">:</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Injectable Penicillin</span></strong><span style=\"font-size:12.0pt\">: Typically administered once every 3 to 4 weeks.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Oral Alternative</span></strong><span style=\"font-size:12.0pt\"> or if the patient prefers not to receive injections, Penicillin V can be used orally at a dose of 250 mg BD.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Second-Line Therapy&nbsp;</span></strong><span style=\"font-size:12.0pt\">(For patients with Penicillin Allergy): <strong>Sulfadiazine</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Third-Line Therapy&nbsp;</span></strong><span style=\"font-size:12.0pt\">(For patients with both Penicillin and Sulfa Allergies): <strong>Macrolides</strong> (Either erythromycin or azithromycin, with erythromycin typically prescribed at 250 mg BD) </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12pt\"><strong>A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>600000 IU Once in 3 weeks for 5 years:&nbsp;</strong>This option would be correct if the duration were 5 years, but since the patient must receive prophylaxis until age 21, this is insufficient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C.</span></strong><span style=\"font-size:12.0pt\"> <strong>1200000 IU Once in 3 weeks for 10 years:</strong> This dosage is for children weighing 27 kg or more. Since the child in this case weighs 26 kg, this dose is too high.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. 1200000 IU Once in 3 weeks for life:</span></strong><span style=\"font-size:12.0pt\"> Lifelong prophylaxis with this dosage is only indicated in patients with severe valvular damage, which is not the case here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For an 11-year-old child weighing 26 kg with a history of streptococcal pharyngitis and no carditis or valvulitis, benzathine penicillin G prophylaxis should be administered at a dose of 600,000 IU every 3 weeks for a duration of 10 years (until the child turns 21 years old).</span></span></p>",
      "correct_choice_id": 45407,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7029,
      "choices": [
        {
          "id": 28084,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Hydrocortisone</span></p>"
        },
        {
          "id": 28085,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Potassium binding resin</span></p>"
        },
        {
          "id": 28086,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Digoxin</span></p>"
        },
        {
          "id": 28087,
          "text": "<p><span style=\"color:#333333;font-size:12pt;\">Calcium gluconate</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">An 18-month-old child with ambiguous genitalia presented to the hospital, his </span><span style=\"font-size:12.0pt;\">BP is 88/68 mm Hg</span><span style=\"font-size:12pt;\">, Serum K<sup>+</sup> is 6 mEq/L, serum sodium is 120 mEq/L. Patient was started on intravenous fluids. What additional specific therapy will you add?</span></p>",
      "unique_key": "Q9436180",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959965,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. Hydrocortisone</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The presentation of an 18-month-old child with ambiguous genitalia, hypertension (BP is 88/68 mm Hg, which is low for this age), hyperkalemia (serum K of 6 mEq/L), and hyponatremia (serum sodium of 120 mEq/L) is suggestive of congenital adrenal hyperplasia (CAH), most likely due to 21-hydroxylase deficiency. This is a common form of CAH and can lead to a decrease in cortisol and aldosterone production, with an accompanying increase in adrenal androgens.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Given this clinical picture, the specific therapy to be added would include:</span></p><p style=\"text-align:justify;\">&nbsp;</p><ol><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Glucocorticoid Replacement:</strong> This is critical to suppress the overproduction of adrenal androgens. Hydrocortisone is commonly used, especially in pediatric patients, due to its short duration of action and lower impact on growth.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Mineralocorticoid Replacement:</strong> Fludrocortisone is usually added to manage the aldosterone deficiency, which is contributing to the hyperkalemia and hyponatremia.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Sodium Chloride Supplements:</strong> In some cases, especially in infants and young children, additional sodium chloride supplements may be necessary to manage hyponatremia.</span></p></li><li><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Monitoring and Adjustment:</strong> Regular monitoring of electrolytes, blood pressure, and growth is necessary to adjust therapy accordingly.</span></p></li></ol><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B</strong>. <strong>Potassium Binding Resins:</strong> While these can be used to treat hyperkalemia, they do not address the underlying cause of the electrolyte imbalance in this scenario, which is likely due to aldosterone deficiency. Therefore, it would not be the first choice.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C</strong>. <strong>Digoxin:</strong> This is used primarily for heart failure and certain arrhythmias, not for the conditions described in this scenario.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D</strong>. <strong>Calcium Gluconate:</strong> This is used in the acute management of severe hyperkalemia to stabilize cardiac membranes. While it might be used in an emergency setting for life-threatening hyperkalemia, it does not address the underlying cause in this case and is not a long-term management strategy.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Therefore, the most appropriate addition to this patient's treatment regimen would be <strong>Hydrocortisone</strong> (option a), as it addresses the underlying cause of the symptoms in CAH. Additionally, monitoring and adjusting mineralocorticoid therapy (like fludrocortisone) would be important in the long-term management, especially given the electrolyte imbalances.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The most appropriate addition to this patient's treatment regimen would be Hydrocortisone, as it addresses the underlying cause of the symptoms in CAH. Additionally, monitoring and adjusting mineralocorticoid therapy (like fludrocortisone) would be important in the long-term management, especially given the electrolyte imbalances.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Reference: - KDT 8<sup>TH</sup>/314</strong></span></p>",
      "correct_choice_id": 28084,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6132,
      "choices": [
        {
          "id": 24497,
          "text": "<p><span style=\"font-size:12pt;\">Repeat serum beta HCG after 48h.</span></p>"
        },
        {
          "id": 24498,
          "text": "<p><span style=\"font-size:12pt;\">Diagnostic laparoscopy.</span></p>"
        },
        {
          "id": 24499,
          "text": "<p><span style=\"font-size:12pt;\">Repeat USG after 3 days.</span></p>"
        },
        {
          "id": 24500,
          "text": "<p><span style=\"font-size:12pt;\">Wait and watch.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22y female is overdue by 2 weeks. She visits the OPD with complaints of vaginal bleeding and abdominal pain on the right side. On Examination, her vitals are stable. Abdomen examination is unremarkable. A bimanual examination reveals a bulky, soft uterus with no tenderness and no adnexal mass. Mild bleeding +. Beta hCG is 1400 IU. An ultrasound reveals a trilaminar endometrium, and both the adnexa are normal. The next best step is?</span>(NEET PG 2022)</p>",
      "unique_key": "Q2601374",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959961,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Repeat serum beta HCG after 48h</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Repeat serum beta hCG after 48h:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">The clinical scenario suggests a pregnancy of unknown location (PUL), which could either be a failing intrauterine pregnancy or an ectopic pregnancy.</span></li><li><span style=\"font-size:12pt;\">The best next step is to repeat the serum beta hCG level after 48 hours. A rise in beta hCG by at least 66% would suggest a viable intrauterine pregnancy, while a plateau or drop would indicate a non-viable pregnancy, such as an ectopic pregnancy or a failing intrauterine pregnancy.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Diagnostic laparoscopy:&nbsp;</strong>Diagnostic laparoscopy is an invasive procedure and is not the immediate next step in the management of a stable patient with PUL. It is reserved for cases where there is a high suspicion of ectopic pregnancy with unstable vital signs or inconclusive non-invasive tests.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Repeat USG after 3 days:&nbsp;</strong>Repeating the ultrasound after 3 days may not provide additional useful information if the initial ultrasound did not show an intrauterine pregnancy. Monitoring beta hCG levels first is more informative and guides the need for further imaging.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Wait and watch:&nbsp;</strong>Simply waiting without further evaluation could delay diagnosis and appropriate management, especially in the case of a potential ectopic pregnancy, which can be life-threatening.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In cases of pregnancy of unknown location (PUL), the next best step is to repeat the serum beta hCG level after 48 hours to differentiate between a viable intrauterine pregnancy and a non-viable pregnancy, such as an ectopic pregnancy or a failing intrauterine pregnancy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/untitled-86.jpg\" alt=\"\" width=\"600\" height=\"669\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: page no 378, William’s Obstetrics 25<sup>th</sup> edition, </strong></span><a href=\"https://www.nice.org.uk/guidance/ng126\"><span style=\"font-size:12pt;\"><strong><u>https://www.nice.org.uk/guidance/ng126</u></strong></span></a></p>",
      "correct_choice_id": 24497,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5646,
      "choices": [
        {
          "id": 22556,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">First trimester</span></span></span></span></p>"
        },
        {
          "id": 22557,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Second trimester</span></span></span></span></p>"
        },
        {
          "id": 22558,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Third trimester</span></span></span></span></p>"
        },
        {
          "id": 22559,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Both A and B</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In which trimester does acute fatty liver manifest most commonly during pregnancy?</span></span><span style=\"font-size:11.0pt\"><span style=\"font-family:&quot;Aptos&quot;,sans-serif\"> (</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NEET PG 2018)</span></span></p>",
      "unique_key": "Q6783663",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959959,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Third trimester </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute fatty liver of pregnancy (AFLP) is a life-threatening medical disorder involving the liver. It most commonly manifests during the late second and third trimester of pregnancy. The diagnosis is made by the Swansea Criteria, wherein 6 or more of the following are required to make the diagnosis:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vomiting</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abdominal pain</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polydipsia, polyuria</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Encephalopathy</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coagulopathy (raised PT, aPTT)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased bilirubin</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased uric acid levels</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased creatinine</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leukocytosis</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoglycemia</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raised liver enzymes</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raised serum ammonia levels</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ascites or bright liver on ultrasound</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Microvascular steatosis on liver biopsy</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute fatty liver of pregnancy (AFLP) most commonly manifests during the third trimester of pregnancy and is diagnosed using the Swansea Criteria.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 2684, Williams Obstetrics 26<sup>th</sup> edition</span></span></strong></span></span></p>",
      "correct_choice_id": 22558,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 43281,
      "choices": [
        {
          "id": 172791,
          "text": "<p><span style=\"font-size:12.0pt;\">Bismuth&nbsp;</span></p>"
        },
        {
          "id": 172792,
          "text": "<p><span style=\"font-size:12.0pt;\">Strassberg&nbsp;</span></p>"
        },
        {
          "id": 172793,
          "text": "<p><span style=\"font-size:12.0pt;\">Stewart- Way&nbsp;</span></p>"
        },
        {
          "id": 172794,
          "text": "<p><span style=\"font-size:12.0pt;\">Hannover&nbsp;</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of these classifications of bile duct injury takes into account the location of injury, and thermal and vascular injury to bile&nbsp;ducts? (INICET Nov 2023)</span></p>",
      "unique_key": "Q4267676",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959952,
      "difficulty_level": "difficult",
      "subjects_id": [
        12
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Hannover&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">When discussing bile duct injuries, several classification systems have been developed to categorize these injuries based on their nature, location, and the extent of damage.&nbsp;</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This system categorizes bile duct injuries based on the anatomical structure involved and the extent of the injury, including vascular injuries.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Bismuth Classification</strong>: Primarily focuses on the location of the bile duct injury in relation to the confluence of the right and left hepatic ducts. This classification is widely used to describe bile duct injuries post-cholecystectomy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Strassberg Classification (also known as the Strassberg-Bismuth classification)</strong>: This is an extension of the Bismuth classification, adding more detail and incorporating the critical view of safety concept. It includes acute injuries, but it is based on location alone. Associated vascular injuries are not included.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Stewart-Way Classification</strong>: This classification focuses on the phase of the operation in which the injury occurs and the type of injury, including thermal damage. It categorizes injuries into four types:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Type I</strong>: Cystic duct leak or leakage from a small peripheral hepatic radicle close to the gallbladder fossa.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Type II</strong>: Injury to the main bile duct that does not involve excision, typically a lateral injury.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Type III</strong>: Complete transaction or excision of a segment of the main bile duct.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Type IV</strong>: Injury involving damage to the hepatic duct confluence and bifurcation.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Stewart-Way classification does not account for associated vascular injury.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bismuth and Strassberg classifications are anatomically based classifications of bile duct injury.</span></p>",
      "correct_choice_id": 172794,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44003,
      "choices": [
        {
          "id": 175671,
          "text": "<p><span style=\"font-size:12.0pt;\">Squamous cell carcinoma</span></p>"
        },
        {
          "id": 175672,
          "text": "<p><span style=\"font-size:12.0pt;\">Basal cell carcinoma</span></p>"
        },
        {
          "id": 175673,
          "text": "<p><span style=\"font-size:12.0pt;\">Melanoma</span></p>"
        },
        {
          "id": 175674,
          "text": "<p><span style=\"font-size:12.0pt;\">Discoid lupus erythematous</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A middle aged Indian male came to Derma OPD with the lesion as shown in the image below. What is the most likely diagnosis?</span>(INICET NOVEMBER 2023)</p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/14/screenshot-2024-05-13-180706.png\" alt=\"\" width=\"300\" height=\"228\"></span></p>",
      "unique_key": "Q8443568",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959824,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Basal cell carcinoma</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The lesion in the image presents as a <strong>pearly nodule</strong> with <strong>telangiectatic vessels</strong>, which is characteristic of BCC.</span></li><li><span style=\"font-size:12.0pt;\">This type of skin cancer most commonly occurs in <strong>sun-exposed areas</strong>, such as the face.</span></li><li><span style=\"font-size:12.0pt;\">&nbsp;The <strong>central ulceration</strong> and <strong>rolled borders</strong> are also indicative of BCC.</span></li><li><span style=\"font-size:12.0pt;\">Given the appearance and the location on the face, BCC is the most likely diagnosis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Squamous Cell Carcinoma (SCC)</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">SCC lesions typically present as <strong>scaly, erythematous plaques or nodules</strong>, often with a <strong>central area of ulceration.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/14/screenshot-2024-05-13-180722.png\" alt=\"\" width=\"500\" height=\"251\"></strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">They can also have a rough, <strong>sandpaper-like texture</strong>.</span></li><li><span style=\"font-size:12.0pt;\">The lesion in the image does not exhibit the typical <strong>keratinized or scaly appearance</strong> that is suggestive of SCC.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Melanoma</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Melanoma usually presents with an <strong>asymmetrical shape, irregular borders, and multiple colors.</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/14/screenshot-2024-05-13-180731.png\" alt=\"\" width=\"300\" height=\"175\"></strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The lesion in the image does not demonstrate these features, making melanoma less likely.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Discoid Lupus Erythematous (DLE)</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">DLE often presents as <strong>erythematous, scaly plaques</strong> with <strong>atrophy and dyspigmentation</strong>, often affecting the face.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/14/screenshot-2024-05-13-180741.png\" alt=\"\" width=\"300\" height=\"324\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The lesion in the image does not show the scale or the degree of atrophy commonly seen with DLE.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Recognize Basal Cell Carcinoma by its pearly appearance, telangiectasia, central ulceration, and rolled borders on sun-exposed skin.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Rooks textbook of dermatology 9<sup>th</sup> edition Page no 141.1-16, 142.1</strong></span></p><p><span style=\"font-size:12.0pt;\"><strong>Bailey &amp; Loves short practice of surgery 27<sup>th</sup> edition page no 599, 604-605, 607-609, 611</strong></span></p>",
      "correct_choice_id": 175672,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19967,
      "choices": [
        {
          "id": 79829,
          "text": "<p><span style=\"font-size:12.0pt;\">Due to opening of Na+ and closure of fast K+ channels</span></p>"
        },
        {
          "id": 79830,
          "text": "<p><span style=\"font-size:12.0pt;\">Due to slow but prolonged opening of Ca2+ channels</span></p>"
        },
        {
          "id": 79831,
          "text": "<p><span style=\"font-size:12.0pt;\">Due to closure of Na+ and opening of slow K+ channel</span></p>"
        },
        {
          "id": 79832,
          "text": "<p><span style=\"font-size:12.0pt;\">Due to Na+/K+ ATPase pump</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the true statement regarding the point marked on the myocardial action potential curve?(NEET PG 2023)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/27/physiology-neet-23-1-8.jpg\" alt=\"\" width=\"500\" height=\"465\"></span></p>",
      "unique_key": "Q1453958",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959958,
      "difficulty_level": "beginner",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Due to slow but prolonged opening of Ca2+ channels</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Marked point on the myocardial action potential curve represents the plateau phase, which is due to the slower and prolonged opening of calcium channels.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Two types of voltage-gated Ca2+ channels (T- and L-types) are present in myocardial cells. The opening of the slower L-type Ca2+ channels are mostly responsible for changes in the action potential. The action potential curve of cardiac muscles consists of 5 phases, as shown.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/27/physiology-neet-23-1-9.jpg\" alt=\"\" width=\"700\" height=\"533\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A</strong>: Incorrect because it mentions both the opening of sodium channels and the closure of fast potassium channels, which is characteristic of Phase 0, not the plateau phase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C</strong>: Incorrect as it attributes the phase to the closure of sodium channels and the opening of slow potassium channels, which more accurately describes the repolarization phase (Phase 3) of the myocardial action potential.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D</strong>: Incorrect because the Na+/K+ ATPase pump, which helps maintain the resting membrane potential, is not the primary driver of the changes observed in the plateau phase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/27/screenshot-2024-05-27-143714.png\" alt=\"\" width=\"1000\" height=\"420\"></p>",
      "correct_choice_id": 79830,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55319,
      "choices": [
        {
          "id": 220737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Head 1/5th palpable per abdomen</span></span></span></p>"
        },
        {
          "id": 220738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">0 station</span></span></span></p>"
        },
        {
          "id": 220739,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">+2 station</span></span></span></p>"
        },
        {
          "id": 220740,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Head on perineum</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Outlet forceps is applied at what station? (FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q9339048",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959826,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Head on perineum</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Outlet forceps are used when the fetal head is at the outlet of the birth canal, which means the head is visible at the perineum. This typically corresponds to a station of +4 or +5 depending on the system used, but &quot;head on perineum&quot; is the most accurate description.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/29/screenshot-2024-08-29-175601.png\" style=\"height:357px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Head 1/5th palpable per abdomen:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This indicates that the head is still relatively high in the birth canal and not at the outlet.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. 0 station:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is when the fetal head is at the level of the ischial spines, which is too high for outlet forceps application.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. +2 station:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This indicates the fetal head is descending but not yet at the perineum. Low forceps might be used at this station, but not outlet forceps.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Outlet forceps are applied when the fetal head is visible at the perineum, indicating it is at the outlet of the birth canal.</span></span></span></p>",
      "correct_choice_id": 220740,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 46975,
      "choices": [
        {
          "id": 187515,
          "text": "<p>The white matter</p>"
        },
        {
          "id": 187516,
          "text": "<p>The gray matter</p>"
        },
        {
          "id": 187517,
          "text": "<p>Both the white and gray matter</p>"
        },
        {
          "id": 187518,
          "text": "<p>Neither the white nor the gray matter</p>"
        }
      ],
      "text": "<p>Binswanger's disease, a form of vascular dementia, primarily affects which part of the brain?&nbsp;(NEET PG 2015)</p>",
      "unique_key": "Q8216548",
      "question_audio": null,
      "question_video": null,
      "map_id": 28959828,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><strong>Correct Answer: A. The white matter</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p>&nbsp;</p><p>Binswanger's disease, also known as subcortical arteriosclerotic encephalopathy, is a prototypical clinical syndrome of vascular cognitive impairment that primarily affects the white matter of the brain. The condition is characterized by progressive confluent subcortical and periventricular white matter disease visible on neuroimaging, with hypoperfusion and hypometabolism. Pathologically, it involves extensive demyelination and destruction of white matter with relative sparing of the subcortical U fibers. Patients typically present with hypertension or systemic vascular disease, and may develop gradual accumulation of focal neurological deficits along with cognitive dysfunction.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option B. The gray matter:</strong> Binswanger's disease specifically targets white matter rather than gray matter. Gray matter disorders typically present with different clinical patterns, such as cortical symptoms including aphasia, agnosia, or apraxia, which are not characteristic of Binswanger's disease.</p><p>&nbsp;</p><p><strong>Option C. Both the white and gray matter:</strong> While some vascular dementias can affect both white and gray matter, Binswanger's disease is defined by its predominant impact on white matter. The pathology shows selective destruction of white matter with relative preservation of gray matter structures.</p><p>&nbsp;</p><p><strong>Option D. Neither the white nor the gray matter:</strong> This is incorrect as Binswanger's disease definitively affects brain tissue, specifically the white matter regions. It is not a disease of other tissues such as blood vessels alone or non-neural brain components.</p><p>&nbsp;</p><p><strong>Educational Objective:</strong>&nbsp;</p><p>&nbsp;</p><p>Binswanger's disease is a subcortical vascular dementia characterized by progressive white matter destruction due to small vessel disease, resulting in a dysexecutive syndrome with apathy, mood alterations, executive dysfunction, and slowed information processing.</p>",
      "correct_choice_id": 187515,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}